Not found

Paolo Zanotti Fregonara, MD, PhD

Associate Research Professor of Neurology, Institute for Academic Medicine
Associate Research Member; Director, PET Core Facility, Research Institute
Houston Methodist
Weill Cornell Medical College

Lab Link


Dr. Paolo Zanotti Fregonara earned his Medical Degree in 1998 and board certification in Nuclear Medicine in 2002 from the University of Milan, Italy. He earned a Master’s Degree in Radiobiology/Radioprotection in 2005 and a PhD in Medical Physics in 2009 from the University of Paris, France. He held appointments at University hospitals in Paris and Bordeaux, the Atomic Energy Commission PET center in Orsay, France, and the Molecular Imaging Branch (NIMH) in Bethesda, Maryland, before rejoining in 2016 the Houston Methodist Research Institute as the director of the PET core imaging lab and chair of the Radiation Safety Committee.

Areas Of Expertise

PET Kinetic modeling Dosimetry

Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging
Zanotti-Fregonara, P, Morgat, C, Champion, C & Hindié, E 2017, European Journal of Nuclear Medicine and Molecular Imaging, pp. 1-2. DOI:

Re: 131I and 124I Accumulation in a Thymic Cyst
Zanotti-Fregonara, P & Hindie, E 2016, Clinical Nuclear Medicine. DOI:

18F-FDG Imaging of Chronic Inflammation Associated With Promontofixation of the Uterus
Meyer, M, Fernandez, P & Zanotti-Fregonara, P 2016, Clinical Nuclear Medicine. DOI:

New fetal dose estimates from 18F-FDG administered during pregnancy: Standardization of dose calculations and estimations with voxel-based anthropomorphic phantoms
Zanotti-Fregonara, P, Chastan, M, Edet-Sanson, A, Ekmekcioglu, O, Erdogan, EB, Hapdey, S, Hindie, E & Stabin, MG 2016, Journal of Nuclear Medicine, vol 57, no. 11, pp. 1760-1763. DOI:

Putative Physiopathological Explanation for the “Sock Sign” in Bone Scans
de Vaugelade, C, Pinaquy, JB, Fernandez, P, Bordenave, L, Hindie, E & Zanotti-Fregonara, P 2016, Clinical Nuclear Medicine. DOI:

Dose deposits from90Y,177Lu,111In, and161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy
Hindie, E, Zanotti-Fregonara, P, Quinto, MA, Morgat, C & Champion, C 2016, Journal of Nuclear Medicine, vol 57, no. 5, pp. 759-764. DOI:

Interest of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for the diagnosis of relapse in patients with spinal infection: A prospective study
Dauchy, FA, Dutertre, A, Lawson-Ayayi, S, de Clermont-Gallerande, H, Fournier, C, Zanotti-Fregonara, P, Dutronc, H, Vital, JM, Dupon, M & Fernandez, P 2016, Clinical Microbiology and Infection, vol 22, no. 5, pp. 438-443. DOI:

Measuring specific receptor binding of a PET radioligand in human brain without pharmacological blockade: The genomic plot
Veronese, M, Zanotti-Fregonara, P, Rizzo, G, Bertoldo, A, Innis, RB & Turkheimer, FE 2016, NeuroImage, vol 130, pp. 1-12. DOI:

Plasma radiometabolite correction in dynamic PET studies: Insights on the available modeling approaches
Tonietto, M, Rizzo, G, Veronese, M, Fujita, M, Zoghbi, SS, Zanotti-Fregonara, P & Bertoldo, A 2016, Journal of Cerebral Blood Flow and Metabolism, vol 36, no. 2, pp. 326-339. DOI:

The PET radioligand 18F-FIMX images and quantifies metabotropic glutamate receptor 1 in proportion to the regional density of its gene transcript in human brain
Zanotti-Fregonara, P, Xu, R, Zoghbi, SS, Liow, JS, Fujita, M, Veronese, M, GladDing, RL, Rallis-Frutos, D, Hong, J, Pike, VW & Innis, RB 2016, Journal of Nuclear Medicine, vol 57, no. 2, pp. 242-247. DOI:

Comparison between three promising ß-emitting radionuclides, 67Cu, 47Sc and 161Tb, with emphasis on doses delivered to minimal residual disease
Champion, C, Quinto, MA, Morgat, C, Zanotti-Fregonara, P & Hindié, E 2016, Theranostics, vol 6, no. 10, pp. 1611-1618. DOI:

New perspectives offered by nuclear medicine for the imaging and therapy of multiple myeloma
Mesguich, C, Zanotti-Fregonara, P & Hindié, E 2016, Theranostics, vol 6, no. 2, pp. 287-290. DOI:

Improved models for plasma radiometabolite correction and their impact on kinetic quantification in PET studies
Tonietto, M, Veronese, M, Rizzo, G, Zanotti-Fregonara, P, Lohith, TG, Fujita, M, Zoghbi, SS & Bertoldo, A 2015, Journal of Cerebral Blood Flow and Metabolism, vol 35, no. 9, pp. 1462-1469. DOI:

Focal inhibitory seizure with prolonged deficit in adult Sturge-Weber syndrome
Aupy, J, Bonnet, C, Arnould, JS, Fernandez, P, Marchal, C & Zanotti-Fregonara, P 2015, Epileptic Disorders, vol 17, no. 3, pp. 328-331.

Neuroinflammation in temporal lobe epilepsy measured using positron emission tomographic imaging of translocator protein
Gershen, LD, Zanotti-Fregonara, P, Dustin, IH, Liow, JS, Hirvonen, J, Kreisl, WC, Jenko, KJ, Inati, SK, Fujita, M, Morse, CL, Brouwer, C, Hong, JS, Pike, VW, Zoghbi, SS, Innis, RB & Theodore, WH 2015, JAMA Neurology, vol 72, no. 8, pp. 882-888.

Fetal radiation dose from 18F-FDG in pregnant patients imaged with PET, PET/CT, and PET/MR
Zanotti-Fregonara, P, Laforest, R & Wallis, JW 2015, Journal of Nuclear Medicine, vol 56, no. 8, pp. 1218-1222. DOI:

The methodology of TSPO imaging with positron emission tomography
Turkheimer, FE, Rizzo, G, Bloomfield, PS, Howes, O, Zanotti-Fregonara, P, Bertoldo, A & Veronese, M 2015, Biochemical Society Transactions, vol 43, pp. 586-592. DOI:

The role of radionuclide imaging in the surgical management of primary hyperparathyroidism
Hindié, E, Zanotti-Fregonara, P, Tabarin, A, Rubello, D, Morelec, I, Wagner, T, Henry, JF & Taïeb, D 2015, Journal of Nuclear Medicine, vol 56, no. 5, pp. 737-744. DOI:

Image-derived input function with factor analysis and a-priori information
Simoncic, U & Zanotti-Fregonara, P 2015, Nuclear Medicine Communications, vol 36, no. 2, pp. 187-193. DOI:

[11C]befloxatone distribution is well correlated to monoamine oxidase A protein levels in the human brain
Zanotti-Fregonara, P & Bottlaender, M 2014, Journal of Cerebral Blood Flow and Metabolism, vol 34, no. 12, pp. 1951-1952. DOI: